ERBB2 and breast cancer: Our study will systematically identify and review available published data from phase II and III interventional clinical trials and observational studies that reported survival outcomes in patients with HER2-positive advanced breast cancer from 1987, when HER2-overexpressing breast cancer was identified as a distinct phenotype, to the present.